Dedifferentiation: Inspiration for Devising Engineering Strategies for Regenerative Medicine ✉ Yongchang Yao 1,2 and Chunming Wang 3
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Ascl1a/Dkk/Β-Catenin Signaling Pathway Is Necessary and Glycogen Synthase Kinase-3Β Inhibition Is Sufficient for Zebrafish Retina Regeneration
Ascl1a/Dkk/β-catenin signaling pathway is necessary and glycogen synthase kinase-3β inhibition is sufficient for zebrafish retina regeneration Rajesh Ramachandran, Xiao-Feng Zhao, and Daniel Goldman1 Molecular and Behavioral Neuroscience Institute and Department of Biological Chemistry, University of Michigan, Ann Arbor, MI 48109 Edited by David R. Hyde, University of Notre Dame, Notre Dame, IN, and accepted by the Editorial Board August 19, 2011 (received for review May 5, 2011) Key to successful retina regeneration in zebrafish are Müller glia necessary for proliferation of dedifferentiated MG in the injured (MG) that respond to retinal injury by dedifferentiating into a cy- retina and that glycogen synthase kinase-3β (GSK-3β) inhibition cling population of retinal progenitors. Although recent studies was sufficient to stimulate MG dedifferentiation into a pop- have identified several genes involved in retina regeneration, ulation of cycling multipotent progenitors in the uninjured ret- the signaling mechanisms underlying injury-dependent MG prolif- ina. Interestingly, Ascl1a knockdown limited the production of eration have remained elusive. Here we report that canonical Wnt neurons by progenitors in the GSK-3β inhibitor-treated retina. signaling controls the proliferation of MG-derived retinal progen- itors. We found that injury-dependent induction of Ascl1a sup- Results pressed expression of the Wnt signaling inhibitor, Dkk, and Ascl1a-Dependent Suppression of dkk Gene Expression in Injured induced expression of the Wnt ligand, Wnt4a. Genetic and phar- Retina. Wnt signaling is a conserved pathway that affects many macological inhibition of Wnt signaling suppressed injury-depen- fundamental developmental processes (18). Deregulated Wnt dent proliferation of MG-derived progenitors. -
Dedifferentiation-Associated Changes in Morphology and Gene Expression in Primary Human Articular Chondrocytes in Cell Culture M
Osteoarthritis and Cartilage (2002) 10, 62–70 © 2002 OsteoArthritis Research Society International 1063–4584/02/010062+09 $35.00/0 doi:10.1053/joca.2001.0482, available online at http://www.idealibrary.com on Dedifferentiation-associated changes in morphology and gene expression in primary human articular chondrocytes in cell culture M. Schnabel*, S. Marlovits†, G. Eckhoff*, I. Fichtel*, L. Gotzen*, V. Ve´csei† and J. Schlegel‡ *Department of Traumatology, Philipps-University of Marburg, Germany †Department of Traumatology, University of Vienna, Austria; Ludwig Boltzmann Institute of Biomechanics and Cell Biology, Vienna, Austria ‡Institute of Pathology, Munich Technical University, Germany Summary Objective: The aim of the present study was the investigation of differential gene expression in primary human articular chondrocytes (HACs) and in cultivated cells derived from HACs. Design: Primary human articular chondrocytes (HACs) isolated from non-arthritic human articular cartilage and monolayer cultures of HACs were investigated by immunohistochemistry, Northern analysis, RT-PCR and cDNA arrays. Results: By immunohistochemistry we detected expression of collagen II, protein S-100, chondroitin-4-sulphate and vimentin in freshly isolated HACs. Cultivated HACs, however, showed only collagen I and vimentin expression. These data were corroborated by the results of Northern analysis using specifc cDNA probes for collagens I, II and III and chondromodulin, respectively, demonstrating collagen II and chondromodulin expression in primary HACs but not in cultivated cells. Hybridization of mRNA from primary HACs and cultivated cells to cDNA arrays revealed additional transcriptional changes associated with dedifferentiation during propagation of chondrocytes in vitro.We found a more complex hybridization pattern for primary HACs than for cultivated cells. -
The Act of Controlling Adult Stem Cell Dynamics: Insights from Animal Models
biomolecules Review The Act of Controlling Adult Stem Cell Dynamics: Insights from Animal Models Meera Krishnan 1, Sahil Kumar 1, Luis Johnson Kangale 2,3 , Eric Ghigo 3,4 and Prasad Abnave 1,* 1 Regional Centre for Biotechnology, NCR Biotech Science Cluster, 3rd Milestone, Gurgaon-Faridabad Ex-pressway, Faridabad 121001, India; [email protected] (M.K.); [email protected] (S.K.) 2 IRD, AP-HM, SSA, VITROME, Aix-Marseille University, 13385 Marseille, France; [email protected] 3 Institut Hospitalo Universitaire Méditerranée Infection, 13385 Marseille, France; [email protected] 4 TechnoJouvence, 13385 Marseille, France * Correspondence: [email protected] Abstract: Adult stem cells (ASCs) are the undifferentiated cells that possess self-renewal and differ- entiation abilities. They are present in all major organ systems of the body and are uniquely reserved there during development for tissue maintenance during homeostasis, injury, and infection. They do so by promptly modulating the dynamics of proliferation, differentiation, survival, and migration. Any imbalance in these processes may result in regeneration failure or developing cancer. Hence, the dynamics of these various behaviors of ASCs need to always be precisely controlled. Several genetic and epigenetic factors have been demonstrated to be involved in tightly regulating the proliferation, differentiation, and self-renewal of ASCs. Understanding these mechanisms is of great importance, given the role of stem cells in regenerative medicine. Investigations on various animal models have played a significant part in enriching our knowledge and giving In Vivo in-sight into such ASCs regulatory mechanisms. In this review, we have discussed the recent In Vivo studies demonstrating the role of various genetic factors in regulating dynamics of different ASCs viz. -
Mouse Digit Tip Regeneration Is Mediated by Fate-Restricted Progenitor Cells
Mouse digit tip regeneration is mediated by fate-restricted progenitor cells Jessica A. Lehoczkya, Benoît Robertb, and Clifford J. Tabina,1 aDepartment of Genetics, Harvard Medical School, Boston, MA 02115; and bInstitut Pasteur, Génétique Moléculaire de la Morphogenèse, Centre National de la Recherche Scientifique, Unité de Recherche Associée 2578, F-75015 Paris, France Contributed by Clifford J. Tabin, November 1, 2011 (sent for review September 19, 2011) Regeneration of appendages is frequent among invertebrates as tation of both the axolotl limb and the zebrafish fin strongly well as some vertebrates. However, in mammals this has been suggest that transdifferentiation does not significantly contribute largely relegated to digit tip regeneration, as found in mice and to the regenerates, and that instead the blastemas are made up of humans. The regenerated structures are formed from a mound of lineage-restricted cell populations (9–11). undifferentiated cells called a blastema, found just below the site Digit tip regeneration has been reported in mammals including of amputation. The blastema ultimately gives rise to all of the mice and juvenile humans (12, 13). Amputations of the terminal tissues in the regenerate, excluding the epidermis, and has classi- phalanx through levels associated with the nail organ are capable cally been thought of as a homogenous pool of pluripotent stem of regeneration, whereas more proximal amputations are not. cells derived by dedifferentiation of stump tissue, although this Intriguingly, mesenchymal nail bed cells in neonatal mice and has never been directly tested in the context of mammalian digit tip humans express the transcription factor Msx1 (14, 15), which is regeneration. -
Stem Cell Therapy and Gene Transfer for Regeneration
Gene Therapy (2000) 7, 451–457 2000 Macmillan Publishers Ltd All rights reserved 0969-7128/00 $15.00 www.nature.com/gt MILLENNIUM REVIEW Stem cell therapy and gene transfer for regeneration T Asahara, C Kalka and JM Isner Cardiovascular Research and Medicine, St Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, MA, USA The committed stem and progenitor cells have been recently In this review, we discuss the promising gene therapy appli- isolated from various adult tissues, including hematopoietic cation of adult stem and progenitor cells in terms of mod- stem cell, neural stem cell, mesenchymal stem cell and ifying stem cell potency, altering organ property, accelerating endothelial progenitor cell. These adult stem cells have sev- regeneration and forming expressional organization. Gene eral advantages as compared with embryonic stem cells as Therapy (2000) 7, 451–457. their practical therapeutic application for tissue regeneration. Keywords: stem cell; gene therapy; regeneration; progenitor cell; differentiation Introduction poietic stem cells to blood cells. The determined stem cells differentiate into ‘committed progenitor cells’, which The availability of embryonic stem (ES) cell lines in mam- retain a limited capacity to replicate and phenotypic fate. malian species has greatly advanced the field of biologi- In the past decade, researchers have defined such com- cal research by enhancing our ability to manipulate the mitted stem or progenitor cells from various tissues, genome and by providing model systems to examine including bone marrow, peripheral blood, brain, liver cellular differentiation. ES cells, which are derived from and reproductive organs, in both adult animals and the inner mass of blastocysts or primordial germ cells, humans (Figure 1). -
Progenitor Cell Therapy for the Treatment of Damaged Myocardium
Progenitor Cell Therapy for the Treatment of Damaged Protocol Myocardium due to Ischemia (20218) Medical Benefit Effective Date: 01/01/11 Next Review Date: 07/22 Preauthorization No Review Dates: 09/10, 07/11, 07/12, 07/13, 07/14, 07/15, 07/16, 07/17, 07/18, 07/19, 07/20, 07/21 This protocol considers this test or procedure investigational. If the physician feels this service is medically necessary, preauthorization is recommended. The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient’s contract at the time the services are rendered. RELATED PROTOCOLS Orthopedic Applications of Stem Cell Therapy (Including Allograft and Bone Substitute Products Used With Autologous Bone Marrow) Stem Cell Therapy for Peripheral Arterial Disease Populations Interventions Comparators Outcomes Individuals: Interventions of interest Comparators of interest Relevant outcomes include: • With acute cardiac are: are: • Disease-specific survival ischemia • Progenitor cell therapy • Standard therapy • Morbid events • Functional outcomes • Quality of life • Hospitalizations Individuals: Interventions of interest Comparators of interest Relevant outcomes -
Differential Contributions of Haematopoietic Stem Cells to Foetal and Adult Haematopoiesis: Insights from Functional Analysis of Transcriptional Regulators
Oncogene (2007) 26, 6750–6765 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc REVIEW Differential contributions of haematopoietic stem cells to foetal and adult haematopoiesis: insights from functional analysis of transcriptional regulators C Pina and T Enver MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK An increasing number of molecules have been identified ment and appropriate differentiation down the various as candidate regulators of stem cell fates through their lineages. involvement in leukaemia or via post-genomic gene dis- In the adult organism, HSC give rise to differentiated covery approaches.A full understanding of the function progeny following a series of relatively well-defined steps of these molecules requires (1) detailed knowledge of during the course of which cells lose proliferative the gene networks in which they participate and (2) an potential and multilineage differentiation capacity and appreciation of how these networks vary as cells progress progressively acquire characteristics of terminally differ- through the haematopoietic cell hierarchy.An additional entiated mature cells (reviewed in Kondo et al., 2003). layer of complexity is added by the occurrence of different As depicted in Figure 1, the more primitive cells in the haematopoietic cell hierarchies at different stages of haematopoietic differentiation hierarchy are long-term ontogeny.Beyond these issues of cell context dependence, repopulating HSC (LT-HSC), -
WNT Signaling in Lung Repair and Regeneration Ahmed A
Molecules and Cells Minireview WNT Signaling in Lung Repair and Regeneration Ahmed A. Raslan1,2 and Jeong Kyo Yoon1,2,* 1Soonchunhyang Institute of Medi-bio Science and 2Department of Integrated Biomedical Science, Soonchunhyang University, Cheonan 31151, Korea *Correspondence: [email protected] https://doi.org/10.14348/molcells.2020.0059 www.molcells.org The lung has a vital function in gas exchange between the functions, the cellular composition and three-dimensional blood and the external atmosphere. It also has a critical structure of the lung must be maintained throughout an or- role in the immune defense against external pathogens ganism’s lifetime. Under normal conditions, the lung shows a and environmental factors. While the lung is classified as a low rate of cellular turnover relative to other organs, such as relatively quiescent organ with little homeostatic turnover, the skin and intestine, which exhibit rapid kinetics of cellular it shows robust regenerative capacity in response to injury, replacement characteristics (Bowden et al., 1968; Kauffman, mediated by the resident stem/progenitor cells. During 1980; Wansleeben et al., 2013). However, after injury or regeneration, regionally distinct epithelial cell populations with damage caused by different agents, including infection, toxic specific functions are generated from several different types compounds, and irradiation, the lung demonstrates a re- of stem/progenitor cells localized within four histologically markable ability to regenerate the damaged tissue (Hogan et distinguished regions: trachea, bronchi, bronchioles, and al., 2014; Lee and Rawlins, 2018; Wansleeben et al., 2013). alveoli. WNT signaling is one of the key signaling pathways If this regeneration process is not completed successfully, it involved in regulating many types of stem/progenitor cells leads to a disruption in proper lung function accompanied by in various organs. -
Newly Identified Aspects of Tumor Suppression by RB
Disease Models & Mechanisms 4, 581-585 (2011) doi:10.1242/dmm.008060 AT A GLANCE Newly identified aspects of tumor suppression by RB Patrick Viatour1,2,3 and Julien Sage1,2 The retinoblastoma (RB) tumor suppressor belongs to a interactions with E2F transcription factors (Chinnam and Goodrich, 2011; Knudsen and Knudsen, 2008). In this article and cellular pathway that plays a crucial role in restricting the the accompanying poster, we review recent evidence indicating that G1-S transition of the cell cycle in response to a large RB acts as a molecular adaptor at the crossroads of multiple number of extracellular and intracellular cues. Research pathways, depending on the cellular context. We also discuss the in the last decade has highlighted the complexity of idea that intact RB function might in some cases promote the early regulatory networks that ensure proper cell cycle steps of tumorigenesis, a provocative possibility for the first- progression, and has also identified multiple cellular identified tumor suppressor. functions beyond cell cycle regulation for RB and its two The RB pathway in cancer family members, p107 and p130. Here we review some Mutations targeting the RB pathway are almost universal in cancer, of the recent evidence pointing to a role of RB as a but different components of this pathway are selectively affected molecular adaptor at the crossroads of multiple in distinct cancer types (see ‘RB mutations in human cancers’ pathways, ensuring cellular homeostasis in different section of the poster). Events that affect upstream members of the contexts. In particular, we discuss the pro- and anti- pathway (e.g. -
Dedifferentiation, Transdifferentiation, and Reprogramming: Future Directions in Regenerative Medicine
82 Dedifferentiation, Transdifferentiation, and Reprogramming: Future Directions in Regenerative Medicine Cristina Eguizabal, PhD1 Nuria Montserrat, PhD1 Anna Veiga, PhD1,2 Juan Carlos Izpisua Belmonte, PhD1,3 1 Center for Regenerative Medicine in Barcelona Address for correspondence and reprint requests Juan Carlos Izpisua 2 Reproductive Medicine Service, Institut Universitari Dexeus, Belmonte, PhD, Gene Expression Laboratory, The Salk Institute for Barcelona, Spain Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 93027 3 Gene Expression Laboratory, The Salk Institute for Biological Studies, (e-mail: [email protected]). La Jolla, California Semin Reprod Med 2013;31:82–94 Abstract The main goal of regenerative medicine is to replace damaged tissue. To do this it is Keywords necessary to understand in detail the whole regeneration process including differenti- ► regenerative ated cells that can be converted into progenitor cells (dedifferentiation), cells that can medicine switch into another cell type (transdifferentiation), and somatic cells that can be ► stem cells induced to become pluripotent cells (reprogramming). By studying the regenerative ► dedifferentiation processes in both nonmammal and mammal models, natural or artificial processes ► transdifferentiation could underscore the molecular and cellular mechanisms behind these phenomena and ► reprogramming be used to create future regenerative strategies for humans. To understand any regenerative system, it is crucial to find the potency and differentiate and how they can revert to pluri- cellular origins of renewed tissues. Using techniques like potency (reprogramming) or switch lineages (dedifferentia- genetic lineage tracing and single-cell transplantation helps tion and transdifferentiation). to identify the route of regenerative sources. These tools were We synthesize the studies of different model systems to developed first in nonmammal models (flies, amphibians, and highlight recent insights that are integrating the field. -
The Retinoblastoma Tumor Suppressor and Stem Cell Biology
Downloaded from genesdev.cshlp.org on September 26, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW The retinoblastoma tumor suppressor and stem cell biology Julien Sage Department of Pediatrics, Department of Genetics, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Institute, Stanford, California 94305, USA Stem cells play a critical role during embryonic develop- control of small cell cycle inhibitors of the INK4 and ment and in the maintenance of homeostasis in adult CIP/KIP families, to which p16Ink4a and p21Cip1,respec- individuals. A better understanding of stem cell biology, tively, belong. The module comprising INK4–CIP/KIP including embryonic and adult stem cells, will allow the cell cycle inhibitors; Cyclin/Cdk complexes; RB and its scientific community to better comprehend a number of two family members, p107 and p130; and E2F transcrip- pathologies and possibly design novel approaches to treat tion factors constitutes the RB pathway in cells. A patients with a variety of diseases. The retinoblastoma second critical component of RB’s control of the G1/S tumor suppressor RB controls the proliferation, differenti- progression is nontranscriptional and connects RB to ation, and survival of cells, and accumulating evidence p27Kip1 stabilization via Cdh1/APC and Skp2. RB has points to a central role for RB activity in the biology of been shown to control many other cellular processes stem and progenitor cells. In some contexts, loss of RB in addition to cell cycle progression in G1, including function in stem or progenitor cells is a key event in the cellular differentiation, by functionally interacting with initiation of cancer and determines the subtype of cancer transcription factors important for the development of arising from these pluripotent cells by altering their fate. -
Corporate Medical Policy Progenitor Cell Therapy for the Treatment of Damaged Myocardium Due to Ischemia
Corporate Medical Policy Progenitor Cell Therapy for the Treatment of Damaged Myocardium Due to Ischemia File Name: progenitor_cell_therapy_for_the_treatment_of_damaged_myocardium_due_to_ischemia Origination: 11/2004 Last CAP Review: 10/2020 Next CAP Review: 10/2021 Last Review: 10/2020 Description of Procedure or Service Ischemia is the most common cause of cardiovascular disease and myocardial damage in the developed world. Despite impressive advances in treatment, ischemic heart disease is still associated with high morbidity and mortality. Current treatments for ischemic heart disease seek to revascularize occluded arteries, optimize pump function, and prevent future myocardial damage. However, current treatments are not able to reverse existing damage to heart muscle. Treatment with progenitor cells (i.e., stem cells) offers potential benefits beyond those of standard medical care, including the potential for repair and/or regeneration of damaged myocardium. The potential sources of embryonic and adult donor cells include skeletal myoblasts, bone marrow cells, circulating blood-derived progenitor cells, endometrial mesenchymal stem cells (MSCs), adult testis pluripotent stem cells, mesothelial cells, adipose-derived stromal cells, embryonic cells, induced pluripotent stem cells, and bone marrow MSCs, all of which are able to differentiate into cardiomyocytes and vascular endothelial cells for regenerative medicine advanced therapy (RMAT). The RMAT designation may be given if: (1) the drug is a regenerative medicine therapy (ie, a cell therapy), therapeutic tissue engineering product, human cell and tissue product, or any combination product; (2) the drug is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs.